VivoSeq
Other

Immunocompromised

0

Pipeline Programs↗

7

Active Trials↗

7

Companies Involved↗

Immunocompromised is an early-stage landscape with 0 programs across 7 companies. The most active players are Pfizer, AstraZeneca, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalBioNTech logo

BioNTech

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed17 · 63%
Recruiting5 · 19%
Not yet recruiting2 · 7%
Terminated2 · 7%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

27 trials

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
Recruiting·MMurdoch Childrens Research Institute·Phase 2·NCT06574789·232 enrolled
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Recruiting·JJohns Hopkins University·Phase 2·NCT07050732·170 enrolled
RSV Vaccination in Immunocompromised Patients.
Recruiting·MMedical University of Vienna·Phase 2·NCT06597916·200 enrolled
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Recruiting·—·Phase 1·NCT04691622·48 enrolled
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03425526·16 enrolled
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
Not yet recruiting·—·Phase 3·NCT07152613·240 enrolled
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Not yet recruiting·VVA Sierra Nevada Health Care System·Phase 4·NCT06271681·45 enrolled
Safety Study to Evaluate FluMist in Immunocompromised Children
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00112112·20 enrolled
Valacyclovir in Immunocompromised Children
Completed·—·Phase 1·NCT00059592·37 enrolled
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT04484935·100 enrolled
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
Completed·UUniversity of Zurich·N/A·NCT01947465·645 enrolled
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
Completed·Pfizer logoPfizer·Phase 2·NCT00556998·26 enrolled
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
Completed·Pfizer logoPfizer·Phase 4·NCT04893811·53 enrolled
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
Completed·UUniversity of Colorado, Denver·Phase 2·NCT01685372·16 enrolled
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
Completed·BioNTech logoBioNTech·Phase 2·NCT04895982·124 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)